Post-earnings recap
Reported
Thu, Feb 26, 2026
EPS actual
$-0.97
EPS est.
$-0.77
EPS surprise
-25.81%
1-day move
+4.80%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kymera Therapeutics reported a larger-than-expected loss per share, which may raise concerns among investors about the company's current performance. Despite the EPS miss, the stock reacted positively, rising 4.8%. This increase could be attributed to investors' optimism about the company's long-term potential despite the current challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.97 | N/A | -25.81% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current operational landscape. They highlighted the need for strategic adjustments but did not offer specific future guidance.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to improve operational efficiency.
No specific guidance was provided for future quarters.